Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) Revenue (2020 - 2025)

Historic Revenue for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to $52.3 million.

  • Cytek Biosciences' Revenue rose 153.98% to $52.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $196.8 million, marking a year-over-year decrease of 217.78%. This contributed to the annual value of $200.5 million for FY2024, which is 385.36% up from last year.
  • As of Q3 2025, Cytek Biosciences' Revenue stood at $52.3 million, which was up 153.98% from $45.6 million recorded in Q2 2025.
  • Over the past 5 years, Cytek Biosciences' Revenue peaked at $58.2 million during Q4 2023, and registered a low of $24.3 million during Q1 2021.
  • For the 5-year period, Cytek Biosciences' Revenue averaged around $43.4 million, with its median value being $44.9 million (2024).
  • As far as peak fluctuations go, Cytek Biosciences' Revenue skyrocketed by 5890.47% in 2021, and later crashed by 758.58% in 2025.
  • Cytek Biosciences' Revenue (Quarter) stood at $38.9 million in 2021, then rose by 24.28% to $48.3 million in 2022, then increased by 20.48% to $58.2 million in 2023, then fell by 1.3% to $57.5 million in 2024, then fell by 9.02% to $52.3 million in 2025.
  • Its Revenue was $52.3 million in Q3 2025, compared to $45.6 million in Q2 2025 and $41.5 million in Q1 2025.